Edwin Torres, NP
Community Health · New York, NYNPI 1053715243
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 42.0% of the total. Among community health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $177.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$32K
- Boehringer Ingelheim$24K
- Bayer$10K
- Lilly USA, LLC$6K
- Corcept Therapeutics$1K
- Esperion Therapeutics, Inc.$589
- plus $3K from 14 others
What the payments were for
- Consulting fees$22,15329%
- Speaking & faculty fees$34,11845%
- Travel & lodging$8,39211%
- Food & beverage$11,58715%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 161 | $32,042 |
| Boehringer Ingelheim | 74 | $23,771 |
| Bayer | 25 | $9,819 |
| Lilly USA, LLC | 30 | $5,923 |
| Corcept Therapeutics | 16 | $1,425 |
| Esperion Therapeutics, Inc. | 9 | $589 |
| Novartis | 26 | $493 |
| Sanofi-aventis U.S. LLC | 22 | $473 |
| AstraZeneca | 24 | $421 |
| Xeris Pharmaceuticals, Inc. | 8 | $283 |
| Abbott | 10 | $253 |
| Johnson & Johnson | 5 | $208 |
| Amgen | 7 | $158 |
| Gilead | 1 | $127 |
| Amarin Pharma, Inc. | 6 | $112 |
| GSK | 1 | $83 |
| Merck | 2 | $48 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Insulet Corporation | 1 | $22 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,289 in reported general payments places this provider in the 95th percentile of 21 community health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 901 | $1,361,742 |
| MounjaroTirzepatide | 463 | $766,722 |
| TrulicityDulaglutide | 570 | $729,296 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 563 | $609,041 |
| Xigduo XrDapaglifloz Propaned/Metformin | 538 | $458,183 |
| Tresiba Flextouch U-200Insulin Degludec | 434 | $270,926 |
| RybelsusSemaglutide | 174 | $266,435 |
| FarxigaDapagliflozin Propanediol | 105 | $115,875 |
| KerendiaFinerenone | 106 | $99,328 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 75 | $85,883 |
| JardianceEmpagliflozin | 63 | $61,619 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 69 | $59,854 |
| SynjardyEmpagliflozin/Metformin Hcl | 51 | $48,889 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 33 | $39,573 |
| Repatha SureclickEvolocumab | 32 | $35,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $32,042 | $1,716,6971,170 claims |
| Lilly USA, LLCMounjaro, Trulicity | $5,923 | $1,496,0181,033 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Trijardy Xr | $23,771 | $759,122710 claims |
| AstraZenecaFarxiga | $421 | $115,875105 claims |
| BayerKerendia | $9,819 | $99,328106 claims |
| MerckJanumet Xr, Segluromet | $48 | $66,48685 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $473 | $10,94216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 community health providers in New York.
Other community health in New York
- Desiree DarrisawNew York$506
- Dawn LawyerNew York$305
- Scott RosmanBinghamton$13K
- Sharon PearceDolgeville$3K
- Danielle MejiasBinghamton$1K
- Megan CoghlanSyracuse$529
- Stacey RosmanBinghamton$457
- Mallory FurnissWest Amherst$442
- Dayle BowerVestal$416
- Richard CrooksonBrooklyn$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.